Cargando…

Correction: Laser-Supported CD133+ Cell Therapy in Patients with Ischemic Cardiomyopathy: Initial Results from a Prospective Phase I Multicenter Trial

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143337/ http://dx.doi.org/10.1371/journal.pone.0107082

Ejemplares similares

Laser-Supported CD133+ Cell Therapy in Patients with Ischemic Cardiomyopathy: Initial Results from a Prospective Phase I Multicenter Trial
por: Assmann, Alexander, et al.
Publicado: (2014)

Correction: Detection and Characterization of CD133(+) Cancer Stem Cells in Human Solid Tumours
por: Tirino, Virginia, et al.
Publicado: (2008)

Systemic Infusion of Expanded CD133(+) Cells and Expanded CD133(+) Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMI
por: Angulski, Addeli B. B., et al.
Publicado: (2019)

Correction: Prognostic Value of Cancer Stem Cell Marker CD133 Expression in Gastric Cancer: A Systematic Review
por: Wen, Lei, et al.
Publicado: (2014)

Correction: Establishment of a Novel Murine Model of Ischemic Cardiomyopathy with Multiple Diffuse Coronary Lesions
por: Nakaoka, Hajime, et al.
Publicado: (2013)

Correction: Reversal of Ischemic Cardiomyopathy with Sca-1(+) Stem Cells Modified with Multiple Growth Factors
por: Li, Ning, et al.
Publicado: (2020)

Correction: Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma
Publicado: (2020)

Correction to Lancet Child Adolesc Health 2021; 5: 133–41
Publicado: (2021)

Correction: Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44 + cancer stem cells to 5 azacytidine in hepatocellular carcinoma
por: Gao, Xiaomei, et al.
Publicado: (2023)

Correction to: Psoriasis as risk factor for non-ischemic dilated cardiomyopathy: a population-based cross-sectional study
por: Alshami, Abbas, et al.
Publicado: (2021)

COMPARE CPM-RMI Trial: Intramyocardial Transplantation of Autologous Bone Marrow-Derived CD133+ Cells and MNCs during CABG in Patients with Recent MI: A Phase II/III, Multicenter, Placebo-Controlled, Randomized, Double-Blind Clinical Trial
por: Naseri, Mohammad Hassan, et al.
Publicado: (2018)

Correction: miR-1915 and miR-1225-5p Regulate the Expression of CD133, PAX2 and TLR2 in Adult Renal Progenitor Cells
por: Sallustio, Fabio, et al.
Publicado: (2015)

Correction to: Picking and Choosing Among Phase I Trials
por: Fisher, Jill A., et al.
Publicado: (2020)

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
por: Wang, Yao, et al.
Publicado: (2018)

Correction: CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
por: Niu, Jiahua, et al.
Publicado: (2023)

Correction: Calreticulin Induces Dilated Cardiomyopathy
por: Lee, Dukgyu, et al.
Publicado: (2013)

Correction: Determinants of Fatigue after First-Ever Ischemic Stroke during Acute Phase
Publicado: (2014)

Correction to: ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial
por: Zilli, Thomas, et al.
Publicado: (2018)

Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133(+) Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy
por: Belotti, Daniela, et al.
Publicado: (2015)

Correction to: The role of microRNA-133b and its target gene FSCN1 in gastric cancer
por: Guo, Lihua, et al.
Publicado: (2020)

Correction: Current practices in ICU delirium management: a prospective multicenter study in the Netherlands
por: Trogrlic, Z, et al.
Publicado: (2013)

Author Correction: Moderate Nucleoporin 133 deficiency leads to glomerular damage in zebrafish
por: Cianciolo Cosentino, Chiara, et al.
Publicado: (2020)

Publisher Correction: Moderate Nucleoporin 133 deficiency leads to glomerular damage in zebrafish
por: Cianciolo Cosentino, Chiara, et al.
Publicado: (2020)

Correction to: The genetic architecture of Plakophilin 2 cardiomyopathy
por: Dries, Annika M., et al.
Publicado: (2021)

CD133 induces tumour-initiating properties in HEK293 cells
por: Canis, Martin, et al.
Publicado: (2012)

Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133(+) cells in ischemic refractory cardiomyopathy trial (RECARDIO)
por: Bassetti, Beatrice, et al.
Publicado: (2018)

Correction to: Genetic Causes of Cardiomyopathy in Children: First Results From the Pediatric Cardiomyopathy Genes Study
Publicado: (2021)

Correction to: The AGING Initiative experience: a call for sustained support for team science networks
por: Garg, Tullika, et al.
Publicado: (2019)

Correction: Brain interstitial pH changes in the subacute phase of hypoxic-ischemic encephalopathy in newborn pigs
por: Remzső, Gábor, et al.
Publicado: (2020)

Correction: A Novel Bayesian Seamless Phase I/II Design
por: Pan, Haitao, et al.
Publicado: (2013)

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
por: Kroschinsky, Frank, et al.
Publicado: (2020)

Correction: Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties
por: Su, Ying-Jhen, et al.
Publicado: (2016)

Correction: End-ischemic hypothermic oxygenated perfusion for extended criteria donors in liver transplantation: a multicenter, randomized controlled trial—HOPExt
por: Pradat, Pierre, et al.
Publicado: (2023)

Correction: Predictors of opioid efficacy in patients with chronic pain: A prospective multicenter observational cohort study
por: Grosen, Kasper, et al.
Publicado: (2019)

Correction to: 10-year follow-up of the Columbus knee prostheses system in a prospective multicenter study
por: Fuchs, Andreas, et al.
Publicado: (2021)

Correction: Local excision versus thrombectomy in thrombosed external hemorrhoids: a multicenter, prospective, observational study
por: Yalcinkaya, Ali, et al.
Publicado: (2023)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

Prospectively Isolated Cancer-Associated CD10(+) Fibroblasts Have Stronger Interactions with CD133(+) Colon Cancer Cells than with CD133(−) Cancer Cells
por: Cui, Lin, et al.
Publicado: (2010)

Mesenchymal stem cell-like properties of CD133(+) glioblastoma initiating cells
por: Pavon, Lorena Favaro, et al.
Publicado: (2016)

Correction to: Actual survival after resection of primary colorectal cancer: results from a prospective multicenter study
por: van den Berg, Inge, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uqnue1q8v93eka8am75gr5h6l6